

DAFTAR PUSTAKA

- Abdallah, C., Udomtecha, D., 2007. Pseudocholinesterase activity: determination and interpretation in pediatric anesthesia. *M.E.J. Anesth*, 19 (2), 423-28.
- Abergel, A., Darcha, C., Chevallier, M., Ughetto, S., Henquell, C., Pol, S., *et al.*, 2004. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. *Eur J Gastroenterol Hepatol*, 16, 1219-1227.
- Abou-Hatab, K., O'Mahony, M.S., Patel, S., Woodhouse, K., 2001. Relationship between age and plasma esterases. *Age Ageing*, 30: 41-5.
- Abraldes, J.G., Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero, Garcia-Pagan, *et al.*, 2007. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. *J Hepatol*; 46: 1040-1046.
- Abraldes, J.G., Albillos, A., Bañares, R., Turnes, J., González, R., García-Pagán, J.C., & Bosch, J., 2009. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterology*, 136(5), 1651-8.
- Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., *et al.*, 2016. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterology*, 150, 1160-1170.
- Aikawa, M., Rabkin, E., Sugiyama, S. *et al.*, 2001. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. *Circulation*, 103, 276-283.
- Akçiçek, F., Ok, E., Duman, S., Kürsad, S., Unsal, A., Alev, M., *et al.*, 1996. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. *Adv Perit Dial.*, 12, 261-5.
- Albanis, E., Friedman, S.L., 2001. Hepatic fibrosis: Pathogenesis and principles of therapy. *Clin Liver Dis*, 5, 315-334.
- Arthur, M.J., 2000. Fibrogenesis II: Metalloproteinases and their inhibitors in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol*, 279, G245-G249.
- Bachem, M.G., Melchior, R., Gressner, A.M., 1989. The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. *J Clin Chem Clin Biochem*, 27, 555-565.
- Baetta, R., Camera, M., Comparato, C., Altana, C., Ezekowitz, M.D., Tremoli, E., 2002. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. *Arterioscler. Thromb. Vasc. Biol.*, 22, 692-698.

- Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H.M., Oyasu, M. *et al.*, 2010. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. *Nat Med*, 16, 1009-1017.
- Bataller, R., Paik, Y.H., Lindquist, J.N., Lemasters, J.J., Brenner, D.A., 2004. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. *Gastroenterology*, 126, 529-540.
- Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., 2014. An assessment by the Statin Liver Safety Task Force: 2014 update. *J Clin Lipid*, 8, S47-S57.
- Benyon, R.C., Iredale, J.P., 2000. Is liver fibrosis reversible? *Gut*, 46, 443-446.
- Benyon, R.C., Iredale, J.P., Goddard, S., Winwood, P.J., Arthur, M.J., 1996. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. *Gastroenterology*, 10, 821-831.
- Berlaimont, V., Mandryko, V., Haskard, D.O., Naoumova, R., Randi, A.M., 2002. Pharmacogenomics in clinical blood samples: the statin pilot study. *Circulation*, 106, II-302.
- Bilzer, M., Roggel, F., Gerbes, A.L., 2006. Role of Kupffer cells in host defense and liver disease. *Liver Int* 26, 1175-1186.
- Bissell, D.M., 1999. Sex and hepatic fibrosis. *Hepatology*, 29(3): 988-989.
- Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F., 2013. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol*; 58: 593-608.
- Bonis, P.A.L., Friedman, S.L., Kaplan, M.M., 2000. Is liver fibrosis reversible? *N Engl J Med*, 344: 452-454.
- Bourcier, T., Libby, P., 2000. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. *Arterioscler. Thromb. Vasc. Biol.*, 20, 556-562.
- Calderon, M.R., Cubeddu, L.X., Goldber, R.B., Schiff, E.R., 2010. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. *Mayo Clin Proc.* 85(4):349-56.
- Canbay, A., Friedman, S., Gores, G.J., 2004. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology*, 39, 273-278.
- Canbay, A., Higuchi, H., Bronk, S.F., Tani, M., Sebo, T.J., Gores, G.J., 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology*, 123, 1323-1330.
- Cheng, H., Rogers, J.D., Sweany, A.E., Dobrinska, M.R., Stein, E.A., Tate, A.C., *et al.*, 1992. Influence of age and gender on the plasma profiles of 3-hydroxy3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. *Pharm Res*, 9: 1629-1633.
- Choi, S.S., Diehl, A.M., 2009. Epithelial to mesenchymal transitions in the liver. *Hepatology*, 50, 2007-2013.
- Cohen, D.E., Anania, F.A., Chalasani, N., 2006. An assesment of statin safety by hepatologists. *Am J Cardiol*; 97: 77C-81C.

- Cohen-Naftaly, M., Friedman, S.L., 2011. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Ther Adv Gastroenterol*, 4(6), 391-417.
- Crisby, M., Nordin-Fredriksson, G., Shah, P.K., Yano, J., Zhu, J., Nilsson, J., 2001. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. *Circulation*, 103, 926–933.
- Cucuianu, M., Nistor, T., Hâncu, N., Orbai, P., Muscurel, C., Stoian, I., 2002. Serum cholinesterase activity correlates with serum insulin, Cpeptide and free fatty acids levels in patients with type 2 diabetes. *Rom J Intern Med.*, 40: 43–51.
- Dahlan, M.S., 2009. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. *Salemba Medika*, Jakarta.
- Dale, K.M., White, C.M, Henyan, N.N., Kluger, J., Coleman, C.I., 2007. Impact of statin dosing intensity on transaminase and creatine kinase. *Am J Med*;120:706-712.
- Dancygier, H., 2010. Clinical scoring systems. In: H. Dancygier (ed.) *Clinical Hepatology*. Verlag Berlin Heidelberg: springer, 289-290.
- Dangas, G., Smith, D.A., Unger, A.H. *et al.*, 2000. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. *Thromb. Haemostasis*, 83, 688–692.
- Darvesh, S., Martin, E., Walsh, R., Rockwood, K., 2004. Differential effects of lipid-lowering agents on human cholinesterases. *Clinical Biochemistry*, 37: 42–49.
- Davis, L., Britten, J.J., Morgan, M., 1997. Cholinesterase: Its significance in anaesthetic practice. *Anaesthesia*, 52: 244–60.
- Desmouliere, A., Darby, I., Costa, A.M., Raccurt, M., Tuchweber, B., Sommer, P. *et al.*, 1997. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. *Lab Invest*, 76, 765-778.
- Dienstag, J.L., Goldin, R.D., Heathcote, E.J., *et al.*, 2003. Histological outcome during long-term lamivudine therapy. *Gastroenterology*, 124, 105-117.
- Dietrich, C. F., 2010. Ultrasonography. In: H. Dancygier (ed.) *Clinical Hepatology*. Verlag Berlin Heidelberg: springer, 359-404.
- Dimmeler, S., Aicher, A., Vasa, M., *et al.*, 2001. HMGCoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. *J. Clin. Invest.*, 108, 391–397.
- Dranoff, J.A., Wells, R.G., 2010. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. *Hepatology* 51, 1438-1444.
- D'Ambrosio, R., Aghemo, A., Rumi, M.G., Ronchi, G., Donato, M.F., Paradis, V., *et al.*, 2012. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. *Hepatology*, 56, 532-543.
- Elsharkawy, A.M., Mann, D.A., 2007. Nuclear factor-kappa B and the hepatic inflammation-fibrosis cancer axis. *Hepatology*, 46, 590-597.

- Eto, M., Kozai, T., Cosentino, F., Joch, H., Luscher, T.F., 2002. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rhokinase and Akt pathways. *Circulation*, 105, 1756–1759.
- Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., Bosch, J., 2009. Angiogenesis in liver disease. *J Hepatol*, 50, 604–20.
- Ferro, D., Basili, S., Alessandri, C., Cara, D., Violi, F., 2000. Inhibition of tissue factor-mediated thrombin generation by simvastatin. *Atherosclerosis*, 149, 111–116.
- Ferro, D., Parrotto, S., Basili, S., Alessandri, C., Violi, F., 2000. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. *J. Am. Coll. Cardiol.*, 36, 427–431.
- Forbes, S.J., Russo, F.P., Rey, V., Burra, P., Rugge, M., Wright, N.A., *et al.*, 2004. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. *Gastroenterology*, 126, 955-963.
- Foucher, J., Chanteloup, E., Vergniol, J., Caste'ra, L., Le Bail, B., Adhoute, X., *et al.*, 2006. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*, 55, 403–408.
- Friedman, S.L., 2004. Mechanisms of hepatic fibrosis and therapeutic implications. *Nat Clin Practice Gastroenterol Hepatol*, 1, 98-105.
- Friedman, S.L., 2008a. Hepatic stellate cells protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev*, 88, 125-172.
- Friedman, S.L., 2008b. Mechanisms of hepatic fibrogenesis. *Gastroenterology*, 134, 1655-1669.
- Gao, B., Radaeva, S., Park, O., 2009. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. *J Leukoc Biol*, 86, 513-528.
- García-Pagán, J.C., Gracia-Sancho, J., Bosch, J., 2012. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. *J Hepatol*, 57, 458–61.
- Garcia-Tsao G., Lim J., Monto A., Yee H., Durfee J., Dieperink E., *et al.*, 2009. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol*, 104, 1802–1829.
- Ghadir, M.R., Riahin, A.A., Havaspour, A., Nooranipour, M., Habibinejad, A.A., 2010. The Relationship between Lipid Profile and Severity of Liver Damage in Cirrhotic Patients. *Hepat Mon*, 10, 285 - 288.
- Ghiassi-Nejad, Z., Friedman, S.L., 2008. Advances in antifibrotic therapy. *Expert Rev Gastroenterol Hepatol*, 2, 803-816.
- Giroux, L.M., Davignon, J., Naruszewicz, M., 1993. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. *Biochim. Biophys. Acta*, 1165, 335–338.
- Gokani R., Jadav P., Shaikh N., Shah R., Chhatriwala M., Patel B., 2014. Serum cholinesterase as diagnostic marker of liver disease. *International Journal of Biomedical And Advance Research*, 05(09), 439-42.

- Guo, J., Loke, J., Zheng, F., Hong, F., Yea, S., Fukata, M. *et al.*, 2009. Functional linkage of cirrhosis predictive single nucleotide polymorphisms of Tolllike receptor 4 to hepatic stellate cell responses. *Hepatology*, 49, 960-968.
- Guy, J., Peters, M.G., 2013. Liver disease in women: the influence of gender on epidemiology, natural History, and patient outcomes. *Gastroenterology & Hepatology*, 9: 633-639.
- Hale, L.P., Craver, K.T., Berrier, A.M., Sheffield, M.V., Case, L.D., Owen, J., 1998. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. *Arterioscler. Thromb. Vasc. Biol.* 18, 1643–1646.
- Handayani, D., Anggraeny, O., Dini, C.Y., Kurniasari, F.N., Kusumastuty, I., Tritisari, K.P., *et al.*, 2015. Nutrition Care Process (NCP). Yogyakarta, *Graha Ilmu*, 28-29.
- Hellerbrand, Wang, S.C., Tsukamoto, H., Brenner, D.A., Rippe, R.A., 1996. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. *Hepatology*, 24, 670-676.
- Hernandez-Perera, O., Perez-Sala, D., Soria, E., Lamas, S., 2000. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. *Circ. Res.*, 87, 616–622.
- Hernandez-Presa, M.A., Martin-Ventura, J.L., Ortego, M., *et al.*, 2002. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. *Atherosclerosis* 160, 49–58.
- Hubbard, R.E., O'Mahony, M.S., Calver, B.L., Woodhouse, K.W., 2008. Plasma esterases and inflammation in ageing and frailty. *Eur J Clin Pharmacol.*, 64: 895–900.
- Huhle, G., Abletshauer, C., Mayer, N., Weidinger, G., Harenberg, J., Heene, D.L., 1999. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. *Thromb. Res.* 95, 229–234.
- Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K., Ueno, H., 2005. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. *Gastroenterology*, 128, 138-146.
- Inoue, I., Goto, S., Mizotani, K., *et al.*, 2000. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1 β , interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in primary endothelial cells. *Life Sci.*, 67, 863–876.
- Issa, R., Zhou, X., Constandinou, C.M., Fallowfield, J., Millward-Sadler, H., Gaca, M.D., *et al.*, 2004. Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. *Gastroenterology*, 126, 1795-1808.
- Ito, D., Ito, O., Mori, N., Muroya, Y., Cao, P.Y., Takashima, K., *et al.*, 2010. Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition

- and Akt activation in the kidney of spontaneously hypertensive rats. *Journal Hypertensi*, 28(11), 2278-88.
- Jain M.K., Ridker P.M., 2005. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. *Nat Rev Drug Discov*; 4: 977-987.
- Jasinska M, Owczarek J, Orszulak-Michalak D., 2007. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. *Pharmacol Rep*;59:483-499.
- Jones, S.P., Gibson, M.F., Rimmer, D.M., Gibson, T.M., Sharp, B.R., Lefer, D.J., 2002. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. *J Am Coll Cardiol*, 40, 1172-8.
- Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, E., *et al.*, 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *The American Journal of Cardiology*, 93, 152-160.
- Jung, Y.K., Yim, H.J., 2017. Reversal of liver cirrhosis: current evidence and expectations. *Korean J Intern Med*, 32, 213-228.
- Karina, 2007. Faktor risiko kematian penderita sirosis hati di RSUP Dr. Kariadi Semarang Tahun 2002-2006. *Artikel karya tulis ilmiah mahasiswa Fakultas Kedokteran Universitas Diponegoro*.
- Katzung, B.G., 2002. Farmakologi Dasar dan Klinik, edisi II. Jakarta, *Salemba Medika*, 671-678.
- Kim, H., Kisseleva, T., Brenner, D.A., 2015. Aging and liver disease. *Curr Opin Gastroenterol*, 31(3): 184-191.
- Kinnman, N., Housset, C., 2002. Peribiliary myofibroblasts in biliary type liver fibrosis. *Front Biosci*, 7, D496-D503.
- Kisseleva, T., Uchinami, H., Feirt, N., Quintana-Bustamante, O., Segovia, J.C., Schwabe, R.F., *et al.*, 2006. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. *J Hepatol*, 45, 429-438.
- Kreuter, M., Bonella, F., Maher, T.M., Costabel, U., Spagnolo, P., Weycker, D., *et al.*, 2017. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. *Thorax*, 72: 148-153.
- Kumar, S., Grace, N.D., Qamar, A.A., 2014. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. *Dig Dis Sci*, 59, 1958-1965.
- Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D.J., *et al.*, 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. *Nat. Med.*, 6, 1004-1010.
- Kusumobroto H.O., 2007. Sirosis Hati. In: S. Ali, A. Nurul, A. L. Laurentius, *et al.* (Ed.) *Buku Ajar Ilmu Penyakit Hati*. Jaya Abadi.
- Kutty, K.M., Payne, R.H., 1994. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. *J Clin Lab Anal.*, 8: 247-250.
- Laroux, F.S., Lefer, D.J., Kawachi, S., *et al.*, 2000. Role of nitric oxide in the regulation of acute and chronic inflammation. *Antioxid. Redox Signaling*, 2, 391-396.
- Laufs, U., Endres, M., Stagliano, N., *et al.*, 2000a. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. *J. Clin. Invest.* 106, 15-24.

- Laufs, U., Gertz, K., Huang, P., Nickenig, G., Bohm, M., Dirnagl, U., Endres, M., 2000b. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. *Stroke AHA Journals*, 31, 2437-49.
- Laufs, U., Gertz, K., Dirnagl, U., Bohm, M., Nickenig, G., Endres, M., 2002. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. *Brain Res.*, 942, 23-30.
- Laufs, U., La Fata, V., Liao, J.K., 1997. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. *J. Biol. Chem.*, 272, 31725-31729.
- Laufs, U., Liao, J.K., 1998. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *J. Biol. Chem.*, 273, 24266-24271.
- Ledoux, S., Laouari, D., Essig, M., *et al.*, 2002. Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of Rho-family GTPases. *Circ. Res.* 90, 420-427.
- Lefler, A.M., Campbell, B., Shin, Y.K., Scalia, R., Hayward, R., Lefler, D.J., 1999. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. *Circulation*, 100, 178-184.
- Lefler, A.M., Scalia, R., Lefler, D.J., 2001. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. *Cardiovasc. Res.*, 49, 281-287.
- Liao, J.K., 2002. Isoprenoids as mediators of the biological effects of statins. *J. Clin. Invest.*, 110, 285-288.
- Libby, P., Aikawa, M., 2002. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. *Nat. Med.*, 8, 1257-1262.
- Llavadot, J., Murasawa, S., Kureishi, Y., *et al.*, 2001. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. *J. Clin. Invest.*, 108, 399-405.
- Lochs, H., Plauth, M., 1999. Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond. *Curr Opin Clin Nutr Metab Care*, 4, 345-349.
- Lopez, S., Peiretti, F., Bonardo, B., Juhan-Vague, I., Nalbone, G., 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. *Atherosclerosis*, 152, 359-366.
- Lopez, S., Peiretti, F., Bonardo, B., *et al.*, 2001. Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages. *J. Cardiovasc. Pharmacol.*, 37, 762-768.
- Luo, W., Meng, Y., Ji, H-L., Pan, C-Q., Huang, S., Yu, C-H., *et al.*, 2012. Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. *PLoS ONE*, 7(3): e34230.

- Malau, A.S., 2012. Karakteristik penderita sirosis hati yang dirawat inap di Rumah Sakit Martha Friska Medan Tahun 2006-2010. *Artikel karya tulis ilmiah mahasiswa Fakultas Kedokteran Universitas Sumatera Utara*.
- Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., *et al.*, 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*, 381, 468-475.
- Marieb, E.N., Hoehn, K., 2007. Human Anatomy and Physiology. Edisi ke-7, 914.
- Mark, Robert, Thomas, Justin, Michael, 2006. Fibrosis and Cirrhosis. *The Merck Manual*, 18(1), 214.
- Maron, D.J., Fazio, S., Linton, M.F., 2000. Current perspectives on statins. *Circulation*, 101, 207-213.
- Marrone G, Russo L, Rosado E, Diana Hide D, Garcia-Cardena~ G, Garcia-Pagan J.C., *et al.*, 2013. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. *J Hepatol*;58:98-103.
- Mason, J.C., 2003. Statins and their role in vascular protection. *Clinical Science*, 105, 251-266.
- Mason, J.C., Ahmed, Z., Mankoff, R., *et al.*, 2002. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. *Circ. Res.* 91, 696-703.
- Mason, R.P., Corbalan, J.J., Jacob, R.F., Dawoud, H., Malinski, T., 2015. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitrooxidative stress and rantes levels in hypertensive rats with diabetes. *Journal Of Physiology And Pharmacology*, 66, 1, 65-72.
- Matsuoka, M., Tsukamoto, H., 1990. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. *Hepatology*, 11, 599-605.
- McCormick, P., 2011. Hepatic Cirrhosis. In : *Sherlock's Diseases Of The Liver And Biliary System 12Th Ed.*, A John Wiley & Sons, Ltd., Publication, 103-117.
- McGirt, M.J., Lynch, J.R., Parra, A., Sheng, H., Pearlstein, R.D., Laskowitz, D.T., *et al.*, 2002. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. *Stroke*, 33, 2950-2956.
- Mencin, A., Kluwe, J., Schwabe, R.F., 2009. Tolllike receptors as targets in chronic liver diseases. *Gut*, 58, 704-720.
- Meng, F., Yin, X., Ma, X., Guo, X.D., Jin, B., Li, H., 2013. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients. *Biomedical Reports*, 1, 265-68.
- Nangle, M.R., Cotter, M.A., Cameron, N.E., 2003. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. *Diabetes*, 52, 2396-2402.

- Niwa, S., Totsuka, T., Hayashi, S., 1996. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. *Int. J. Immunopharmacol.*, 18, 669–675.
- Nurdjanah, S., 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. Edisi V Jilid I, Jakarta: *Interna Publishing*, 668-673.
- Nurdjanah, S., 2014. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. Edisi VI Jilid II, Jakarta: *Interna Publishing*, 1978-83.
- O'Driscoll, G., Green, D., Taylor, R.R., 1997. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation*; 95: 1126–1131.
- Ohara, Y., Peterson, T.E., Sayegh, H.S., Subramanian, R.R., Wilcox, J.N., Harrison, D.G., 1995. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. *Circulation*, 92, 898–903.
- Ostergaard, D., Viby-Mogensen, J., Hanel, H.K., Skovgaard, L.T., 1988. Half-life of plasma cholinesterase. *Acta Anaesthesiol Scand.*, 32: 266–9.
- Pan, Y., Muzyka, J.L., Zhan, C.G., 2009. Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation. *J Phys Chem B.*, 113: 6543–52.
- Park, J.G., Tak, W.Y., Park, S.Y., Kweon, Y.O., Jang, S.Y., Lee, Y.R., *et al.*, 2017. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease A Korean nationwide, multicenter, retrospective, observational, cohort study. *Medicine*, 96:24.
- Pedersen, T.R., 2010. Pleiotropic effects of statins: Evidence against benefits beyond LDL-cholesterol lowering. *American Journal of Cardiovascular Drugs*, 10 Suppl 1, 10–7.
- Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J.F., Bell, B.P., 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of Hepatology*, 45, 529-30.
- Pruefer, D., Makowski, J., Schnell, M., Buerke, U., Dahm, M., Oelert, H., *et al.*, 2002. Simvastatin inhibits inflammatory properties of *Staphylococcus aureus* α -toxin. *Circulation*, 106, 2104–2110.
- Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., 1973. Transection of the oesophagus for bleeding oesophageal varices. *The British journal of surgery*, 60 (8), 646–9.
- Rajamannan, N.M., Subramaniam, M., Stock, S.R., Stone, N.J., Springett, M., Ignatiev, K.I., *et al.*, 2005. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. *Heart Journal*, 91, 806–810.
- Rambaldi, A., Gluud, C., 2005. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. *Cochrane Database Syst Rev*, 2, CD002148.
- Rao, S.V., Kiran, V.S.R., Indira, S., 2011. A comparative study of pseudocholinesterase and liver function test in cirrhosis of liver, infective

- hepatitis and obstructive jaundice: a case control study. *Journal of Clinical and Diagnostic Research*, 5(4), 729-32.
- Rockey, D.C., 2008. Current and future anti-fibrotic therapies for chronic liver disease. *Clin Liver Dis*, 12, 939-962.
- Rojkind, M., Giambrone, M.A., Biempica, L., 1979. Collagen types in normal and cirrhotic liver. *Gastroenterology*, 76, 710-719.
- Romano, M., Mezzetti, A., Marulli, C., *et al.*, 2000. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. *J. Invest. Med.*, 48, 183–189.
- Rosenson, R.S., 2003. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. *Expert Rev. Cardiovasc. Ther.*, 1, 495–505.
- Rossoni, L.V., Wareing, M., Wenceslau, C.F., Al-Abri, M., Cobb, C., Austin, C., 2011. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. *Clinical Science*, 121, 449–458.
- Safadi, R., Ohta, M., Alvarez, C.E., Fiel, M.I., Bansal, M., Mehal, W.Z., *et al.*, 2004. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. *Gastroenterology*, 127, 870-882.
- Sahebkar, A., Kotani, K., Serban, C., Ursoniu, S., Mikhailidis, D.P., Jones, S.R., *et al.*, 2015. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. *Atherosclerosis*;241:433-442.
- Santarpia, L., Grandone, I., Contaldo, F., Pasanisi, F., 2013. Butyrylcholinesterase as a prognostic marker: a review of the literature. *J Cachexia Sarcopenia Muscle*, 4: 31–39.
- Saragih, G.G., Waleleng, B.J., Haroen, H., 2016. Gambaran gangguan hemostasis pada penderita sirosis hati yang dirawat di RSUP Prof. Dr. R. D. Kandou periode Agustus 2013 – Agustus 2015. *Jurnal e-Clinic (eCl)*, 4(1), 128-33.
- Schnabl, B., Brandl, K., Fink, M., Gross, P., Taura, K., Gabele, E., *et al.*, 2008. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. *Biochem Biophys Res Commun*, 375, 210-214.
- Scholten, D., Osterreicher, C.H., Scholten, A., Iwaisako, K., Gu, G., Brenner, D.A., *et al.*, 2010. Genetic labeling does not detect epithelial to mesenchymal transition of cholangiocytes in liver fibrosis in mice. *Gastroenterology*, 139, 987-998.
- Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., *et al.*, 2007. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med*, 13, 1324-1332.
- Sherlock, S., Dooley, J.D., 2002. Hepatic Cirrhosis. In: S. Sherlock and J. D. Dooley (eds.) *Diseases of the Liver and Biliary System* Eleventh ed.: Blackwell Science.

- Sibuea, N.A., 2014. Karakteristik penderita sirosis hati rawat inap di Rumah Sakit Umum Pusat Haji Adam Malik Tahun 2012. *Artikel karya tulis ilmiah mahasiswa Fakultas Kedokteran Universitas Sumatera Utara*.
- Simon, T.G., King, L.Y., Zheng, H., Chung, R.T., 2015. Statin Use is Associated with a Reduced Risk of Fibrosis Progression in Chronic Hepatitis C. *J Hepatol.*; 62(1): 18–23.
- Soliday, F.K., Conley, Y.P., Henker, R., 2010. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. *AANA Journal*, 78(4), 313-20.
- Stalker, T.J., Lefer, A.M., Scalia, R., 2001. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts antiinflammatory effects on the microvascular endothelium: the role of mevalonic acid. *Br. J. Pharmacol.*, 133, 406–412.
- Starr, S.P., Raines, D., 2011. Cirrhosis: diagnosis, management, and prevention. *Am Fam Physician*, 84(12), 1353-9.
- Taha, H.A., Waked, I.A., 2010. Liver disease on the Nile: an association since millennia. *Nile Liver Journal*, 1(1), 1-6.
- Takemoto, M., Liao, J.K., 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arterioscler. Thromb. Vasc. Biol.*, 21, 1712–1719.
- Taprantzia, D., Zisimopoulos, D., Thomopoulos, K.C., Spiliopoulou, I., Georgiou, C.D., Tsiaoussis, G., *et al.*, 2018. Propranolol reduces systemic oxidative stress and endotoxemia in cirrhotic patients with esophageal varices. *Annals of Gastroenterology*, 31, 224-230.
- Taura, K., Miura, K., Iwaisako, K., Osterreicher, C.H., Kodama, Y., Penz-Osterreicher, M., *et al.*, 2010. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. *Hepatology*, 51, 1027-1036.
- Terai, S., Ishikawa, T., Omori, K., Aoyama, K., Marumoto, Y., Urata, Y., *et al.*, 2006. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. *Stem Cells*, 24, 2292-2298.
- Trocha, M., Merwid-L, A., Szuba, A., Chlebda, E., Pieoeniewska, M., Sozański, T., *et al.*, 2010. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. *Pharmacological Reports*, 62, 343-351.
- Tsochatzis, E.A., Bosch, J., Burroughs, A.K., 2014. Liver cirrhosis. *Royal Free Sheila Sherlock Liver Centre*, S0140-6736(14), 60121-5.
- Vasa, M., Fichtlscherer, S., Adler, K., *et al.*, 2001. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. *Circulation*, 103, 2885–2890.
- Wagner, A.H., Kohler, T., Ruckschloss, U., Just, I., Hecker, M., 2000. Improvement of nitric oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. *Arterioscler. Thromb. Vasc. Biol.*, 20, 61–69.
- Walter, D.H., Rittig, K., Bahlmann, F.H., *et al.*, 2002. Statin therapy accelerates re-endothelialization: a novel effect involving mobilization and

- incorporation of bone marrow-derived endothelial progenitor cells. *Circulation*, 105, 3017-3024.
- Wanless, I.R., Wong, F., Blendis, L.M., Greig, P., Heathcote, E.J., Levy, G., 1995. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. *Hepatology*, 21, 1238-47.
- Watanabe, A., Hashmi, A., Gomes, D.A., Town, T., Badou, A., Flavell, R.A., *et al.*, 2007. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. *Hepatology*, 46, 1509-1518.
- Wells, R.G., 2010. The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow?. *Hepatology*, 51, 737-740.
- Werner, N., Priller, J., Laufs, U., *et al.*, 2002. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. *Arterioscler. Thromb. Vasc. Biol.*, 22, 1567-1572.
- Wheeler, M.D., Kono, H., Yin, M., Nakagami, M., Uesugi, T., Arteel, G.E., *et al.*, 2001. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. *Free Radic Biol Med*, 31, 1544-1549.
- Whittaker, M., 1980. Plasma cholinesterase variants and the anaesthetist. *Anaesthesia*. 35 (2): 174-197.
- Williams, H.M., Lamotta, R.V., Wetstone, H.J., 1957. Studies of cholinesterase Activity III: Serum cholinesterase in obstructive jaundice and malignant disease. *Gastroenterology*, 33: 58.
- Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P.A., *et al.*, 2007. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. *Immunity*, 26, 117-129.
- Witztum, J.L., 1996. Drugs Used in the Treatment of Hyperlipoproteinemias. In: Molinoff, P.B., and Ruddon, R.W. (editor). Goodman & Gilman's The Pharmacological Basis Of Therapeutics. Edisi 9. *New York : McGraw Hill, Inc.*, 887.
- Yoshiji, H., Kuriyama, S., Miyamoto, Y., Thorgeirsson, U.P., Gomez, D.E., Kawata, M., *et al.*, 2000. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. *Hepatology*, 32, 1248-1254.
- Zafra, C., Abalde, J.G., Turnes, J., Berzigotti, A., Fernández, M., Garcia-Pagán, J.C., *et al.*, 2004. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. *Gastroenterology*, 126(3), 749-55.
- Zdrengea, D., Bodizs, G., Predescu, D., Oprea, M., Zdrengea, M., 2002. The effect of Simvastatin upon serum pseudocholinesterase and plasmatic factor VII. *Rom J Intern Med*, 40: 3-9.